Перейти к основной навигации
Перейти к поиску
Перейти к основному содержанию
Сортировать по:
INIS
cathepsin
100%
humans
63%
antigens
46%
serine
38%
processing
38%
peptides
38%
proteins
37%
dendrites
31%
applications
30%
glioblastomas
28%
molecules
28%
neutrophils
24%
histocompatibility complex
23%
surfaces
22%
probes
19%
patients
17%
regulations
16%
inflammation
16%
cleavage
15%
mice
13%
inhibition
13%
cancer
12%
compartments
12%
detection
12%
cathepsins
12%
levels
12%
substrates
11%
amino acids
11%
viruses
10%
diabetes mellitus
10%
diseases
9%
control
9%
myelin
9%
blood
9%
natural killer cells
9%
ligands
9%
lysosomes
8%
tetanus
8%
cytokines
8%
tissues
8%
lactoferrin
7%
tumors
7%
therapy
7%
enzymes
7%
monocytes
7%
stem cells
7%
proteolysis
7%
in vitro
7%
induction
7%
cysteine
7%
Immunology and Microbiology
Peptides
25%
Proteinase
24%
Cell Surface
24%
Serine
23%
Protease
20%
Major Histocompatibility Complex
20%
Natural Killer Cell
18%
Antigen Presentation
17%
Dendritic Cell
17%
Immune System
17%
T Cell
15%
Protein Degradation
13%
Neutrophil
13%
B Cell
12%
Innate Immune System
11%
Adaptive Immune System
10%
Immune Response
10%
T-Helper Cell
9%
MHC Class II
9%
Antigen
8%
Immunocompetent Cell
8%
Regulatory T Cell
8%
Diabetes Mellitus Type 1
7%
MHC Class I
7%
Biotin
7%
Autoantigen
7%
Amino Acid
6%
Antigen-Presenting Cell
6%
Cytotoxic T-Cell
6%
Peripheral Blood Mononuclear Cell
6%
Infectious Agent
6%
Autoimmunity
6%
Monocyte
6%
Antigen Presenting Cell
5%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
Amino Acid Sequence
5%
Lung
5%
Tumor Cell
5%
Keyphrases
Cathepsin G
41%
Serine Protease
19%
Neutrophil Elastase
17%
MHC-I
13%
Proteolytic Activity
12%
Antigen-presenting Cells
11%
Glioblastoma Cells
10%
Activity-based Probes
9%
Cleavage Site
8%
Protease
8%
Neutrophils
8%
Antigen Processing
7%
Glioblastoma
7%
Lactoferrin
7%
Immune Response
7%
Cathepsin
6%
Cell Surface
6%
Proteinase 3
5%
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
5%
Cell Permeable
5%
Spleen
5%
Amino Acid Substitution
5%
SARS-CoV-2 Omicron
5%